(+)-JRT, a de novo synthesized LSD analogue (two-atom transposition), retains potent neuroplasticity-promoting effects while markedly reducing hallucinogenic liability. It offers a path toward treating depression, addiction, and cognition deficits in patients (e.g., SCZ, psychosis family history) for whom classical psychedelics are contraindicated.
- **Mechanism:** promotes cortical spinogenesis / dendritic growth (same pathway as LSD)
- **Selectivity:** improved receptor pharmacology; does *not* amplify psychosis-associated behavioral or gene-expression signatures
- **Behavioral readouts:** antidepressant- and cognition-relevant assay effects
- **Design principle:** minimal structural edit → "nonhallucinogenic psychoplastogen" class
- **Mechanism:** promotes cortical spinogenesis / dendritic growth (same pathway as LSD)
- **Selectivity:** improved receptor pharmacology; does *not* amplify psychosis-associated behavioral or gene-expression signatures
- **Behavioral readouts:** antidepressant- and cognition-relevant assay effects
- **Design principle:** minimal structural edit → "nonhallucinogenic psychoplastogen" class
